SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Imago BioSciences today announced the presentation of data at the 2020 Virtual European Hematology Association (EHA) meeting relating to the clinical trial of bomedemstat (IMG-7289) for the treatment of advanced myelofibrosis. The abstract published online in May included an analysis of data from 34 patients. The presentation today as a poster reflects a more extensive analysis of a larger patient population based on a later data cutoff.
“The poster enumerates spleen volume reductions and improvements in Total Symptom Scores in a majority of patients. Additionally, there were improvements in hemoglobin with patients transitioning from transfusion-dependence to transfusion-independence and bone marrow fibrosis improvements,” said Kristen Petitt, MD, Assistant Professor of Medicine at the University of Michigan, Rogel Cancer Center, in Ann Arbor. “In this ongoing study, the preliminary data indicate that bomedemstat has significant clinical activity as monotherapy in a myelofibrosis patient population with advanced disease and no therapeutic alternatives.”
Data Highlights
Bomedemstat (IMG-7289) monotherapy in intermediate-2/high-risk patients with myelofibrosis who have become intolerant or resistant to a JAK inhibitor
-
Of evaluable patients at 24 weeks:
- 83% had spleen volume reductions
- 86% demonstrated reductions in Total Symptom Scores (TSS)
- 70% of patients had stable or improved hemoglobin
- 71% of patients had a stable or improved BM fibrosis score
- >90% of patients with elevated circulating inflammatory cytokines showed significant reductions
Safety
Bomedemstat (IMG-7289) in patients with myelofibrosis was generally well tolerated. No dose-limiting toxicities were observed, and a maximum tolerated dose was not identified.
There were 723 adverse events (AEs) reported, of which 215 were attributed to bomedemstat. Only four SAEs -- painful splenomegaly, heart failure, headache, rectal bleeding (all Grade 3) -- were deemed by the Investigator to be related to bomedemstat. There were no Grade 5 events related to bomedemstat.
The most common treatment-emergent AEs deemed related to bomedemstat was dysgeusia (33%).
For further details, please see the 2020 EHA abstract and poster on Imago’s website at www.imagobio.com.
Poster Presentation
TITLE: A PHASE 2 STUDY OF BOMEDEMSTAT (IMG-7289), A LYSINE-SPECIFIC DEMETHYLASE-1 (LSD1) INHIBITOR, FOR THE TREATMENT OF MYELOFIBROSIS (MF)
Session: Myeloproliferative Neoplasms—Clinical
Date and Time: June 12, 2020, 8:30 AM CEST/2:30 AM EDT
About Bomedemstat (IMG-7289)
Bomedemstat is being evaluated in an open-label Phase 2 clinical trial (www.myelofibrosisclinicalstudy.com) for the treatment of myelofibrosis (MF), a bone marrow cancer that interferes with the production of blood cells. The endpoints include spleen volume reduction and symptom improvement at 12 and 24 weeks of treatment. Bomedemstat is used as monotherapy in patients who are resistant to, intolerant of, or ineligible for ruxolitinib.
Bomedemstat is a small molecule developed by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme shown to be vital in cancer stem/progenitor cells, particularly neoplastic bone marrow cells. In non-clinical studies, IMG-7289 demonstrated robust in vivo anti-tumor efficacy across a range of myeloid malignancies as a single agent and in combination with other chemotherapeutic agents. Bomedemstat (IMG-7289) is an investigational agent currently being evaluated in ongoing clinical trials (ClinicalTrials.gov Identifier: NCT03136185 and NCT04254978). Bomedemstat has FDA Orphan Drug and Fast Track Designation for the treatment of myelofibrosis, essential thrombocythemia and acute myeloid leukemia.
About Imago BioSciences
Imago BioSciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics targeting epigenetic enzymes. Imago has developed a series of compounds that inhibit LSD1, an epigenetic enzyme critical for cancer stem cell function and differentiation. Imago is advancing the clinical development of its first LSD1 inhibitor, bomedemstat, for the treatment of myeloid neoplasms including myelofibrosis and essential thrombocythemia. Imago is backed by leading strategic and venture investors including a fund managed by Blackstone Life Sciences, Frazier Healthcare Partners, Omega Funds, Amgen Ventures, MRL Ventures, Highlight Capital, Pharmaron, Greenspring Associates and Xeraya Capital. The company is based in South San Francisco, California. To learn more, visit www.imagobio.com.